Table 2.
Role of other types of exosomal cargos in pancreatic cancer diagnosis.
| Exosomal miRNA | Origin or cell source | Biomarker or other roles | Number of patients | Year | Ref. |
|---|---|---|---|---|---|
| miR-17-5p | Serum | 1) Diagnostic for PC advanced stage 2) Metastasis |
49 | 2013 | (131) |
| Plasma | Diagnostic biomarker for dividing PC and non-PC | 20 | 2015 | (132) | |
| miRNA-21 | 1) Portal vein blood (serum) 2) Pancreatic juice |
1) Diagnostic chronic pancreatitis 2) Early diagnostic 3) Prognostic 4) Recurrence diagnostic 5) Tumor survival evaluation |
49 | 2013 | (131) |
| 55 | 2019 | (133) | |||
| 35 | 2019 | (121) | |||
| miRNA-210 | 1) Peripheral blood | 1) Early diagnosis 2) Tumor stage |
40 | 2020 | (134) |
| 2) PSC | Prognostic (gemcitabine resistance) | In vitro | 2020 | (135) | |
| miRNA-10b | Peripheral blood (serum) | Early diagnosis | 36 | 2020 | (136) |
| 40 | 2017 | (137) | |||
| miRNA-3976 | Serum | Early diagnosis | 190 | 2015 | (138) |
| miR-222 | 1) Peripheral blood 2) PCC |
1) Tumor stage diagnosis 2) Survival evaluation 3) Prognostic |
Cell line/in vitro | 2018 | (139) |
| miRNA-1246 | Peripheral blood (serum) | Early diagnosis | 15 | 2017 | (139) |
| miRNA-451a | 1) Portal vein blood | 1) Recurrence diagnostic 2) Tumor survival evaluation |
55 | 2019 | (133) |
| 2) Plasma | Prognostic and recurrence | 46 | 2018 | (140) | |
| miRNA-155 | 1) Pancreatic juice | 1) Early diagnosis 2) Prognostic |
35 | 2019 | (121) |
| 2) PCC | Prognostic for gemcitabine resistance | 1) In vitro | 2017 | (141) | |
| 2) In vivo = 45 | |||||
| miRNA-4644 | Saliva | Early diagnosis | 12 | 2016 | (142) |
| miR-3607-3p | NK cells | Prognostic | 40 | 2019 | (122) |